Intuitive Surgical’s Q3 2026 da Vinci procedure growth market reflects trader focus on U.S. moderation offsetting international strength ahead of the October 20 earnings release. Management maintained its full-year 2026 guidance of 13.5–15.5% growth, expecting results near the midpoint after Q2 worldwide da Vinci procedures rose 15% (U.S. +12%, OUS +20%). U.S. volumes have slowed from ACA premium subsidy expirations and the law of large numbers in established procedures, while OUS momentum in Europe and Asia and rising da Vinci 5 utilization provide partial offsets. Q3 faces tougher year-over-year comparisons versus 19% growth in Q3 2025. These dynamics support the 12.5–15% band as the leading outcome, with limited probability assigned to 17.5%+ growth.